Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Company Growth (employees)
Cambridge, US
Size (employees)
7,400 (est)
Biogen was founded in 1978 and is headquartered in Cambridge, US

Key People at Biogen

Michel Vounatsos

Michel Vounatsos

Walter Charles

Walter Charles

Chief Procurement Officer

Biogen Office Locations

Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St

Biogen Data and Metrics

Biogen Financial Metrics

Biogen's revenue was reported to be $11.4 b in FY, 2016 which is a 6% increase from the previous period.
$, USD

Revenue (FY, 2016)

11.4 b

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

3.7 b

EBIT (FY, 2016)

5.2 b

Market capitalization (23-Jun-2017)

59.5 b

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

2.3 b
Biogen's current market capitalization is $59.5 b.
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


6.9 b9.7 b10.8 b11.4 b

Revenue growth, %



4.9 b5.2 b

EBIT margin, %


Net Income

1.9 b2.9 b3.6 b3.7 b
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


602.6 m1.2 b1.3 b2.3 b

Accounts Receivable

824.4 m1.3 b1.2 b1.4 b


659 m804 m893.4 m1 b

Current Assets

3.2 b4.7 b6.7 b8.7 b


1.8 b1.8 b2.2 b2.5 b


1.2 b1.8 b2.7 b3.7 b

Total Assets

11.9 b14.3 b19.5 b22.9 b

Accounts Payable

219.9 m229.2 m267.4 m279.8 m

Total Debt

1.2 b

Current Liabilities

1.8 b2.2 b2.6 b3.4 b

Additional Paid-in Capital

4 b4.2 b

Retained Earnings

6.3 b9.3 b12.2 b15.1 b

Total Equity

8.6 b10.8 b9.4 b12.1 b

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.4 x1.3 x2.1 x1.9 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.9 b2.9 b3.6 b3.7 b

Depreciation and Amortization

688.2 m600.4 m682.7 m

Accounts Receivable

(130 m)(510 m)29 m(240 m)


(240 m)(190 m)(170 m)(170 m)

Purchases of PP&E

(246.3 m)(287.8 m)(643 m)(616.1 m)

Cash From Investing Activities

(1.6 b)(1.5 b)(4.6 b)(2.5 b)

Cash From Financing Activities

(716.5 m)(755.9 m)
$, USDY, 2016


1.6 m

Financial Leverage

1.9 x

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016
FY, 2016

Phase III Trials


Phase II Trials


Training Provided, no. of people

40 k

Phase I Trials


Biogen Market Value History

Biogen Median Salaries

Source: 109 public H-1B filings from Biogen

Biogen Online and Social Media Presence

Biogen News and Updates

Biogen Company Life and Culture

You may also be interested in